Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11
- PMID: 12384538
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11
Abstract
Combining anticancer drugs with different mechanisms of action has the potential to enhance antitumor effect. CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly effective in the treatment of a variety of cancers. However, its clinical usage is often complicated by late diarrhea. A number of studies have shown that cyclooxygenase (COX)-2 is overexpressed in many forms of human tumors, suggesting that COX-2 inhibition may be useful in the treatment of cancer. In this study, we used two mouse tumor models (HT-29 and colon-26 cells) to evaluate the effect of combining CPT-11 with celecoxib on tumor growth. We also assessed the involvement of COX-2 in the pathogenesis of CPT-11-induced late diarrhea using a rat model. Results indicate that celecoxib enhances the antitumor effect of CPT-11 and reduces the severity of late diarrhea in a dose-dependent manner. The extended benefits of combining celecoxib with CPT-11 may significantly improve the outcome of cancer patients.
Similar articles
-
Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.Cancer Res. 2003 Oct 15;63(20):6726-34. Cancer Res. 2003. PMID: 14583467
-
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.Cancer Res. 2002 Nov 15;62(22):6706-11. Cancer Res. 2002. PMID: 12438270
-
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.FASEB J. 2001 Dec;15(14):2742-4. doi: 10.1096/fj.01-0299fje. Epub 2001 Oct 15. FASEB J. 2001. PMID: 11606477
-
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.Oncology (Williston Park). 2003 Jul;17(7 Suppl 7):22-6. Oncology (Williston Park). 2003. PMID: 12886870 Review.
-
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.Oncology (Williston Park). 2003 May;17(5 Suppl 5):15-24. Oncology (Williston Park). 2003. PMID: 12800601 Review.
Cited by
-
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.Clin Exp Metastasis. 2004;21(4):339-46. doi: 10.1023/b:clin.0000046140.19131.19. Clin Exp Metastasis. 2004. PMID: 15554390
-
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.Br J Cancer. 2009 May 19;100(10):1581-8. doi: 10.1038/sj.bjc.6605051. Epub 2009 Apr 28. Br J Cancer. 2009. PMID: 19401694 Free PMC article.
-
Ocoxin as a complement to first line treatments in cancer.Int J Med Sci. 2021 Jan 1;18(3):835-845. doi: 10.7150/ijms.50122. eCollection 2021. Int J Med Sci. 2021. PMID: 33437220 Free PMC article. Review.
-
Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment.Pharmaceuticals (Basel). 2025 Mar 2;18(3):359. doi: 10.3390/ph18030359. Pharmaceuticals (Basel). 2025. PMID: 40143136 Free PMC article. Review.
-
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.Pharm Res. 2006 Sep;23(9):2094-106. doi: 10.1007/s11095-006-9074-6. Epub 2006 Aug 11. Pharm Res. 2006. PMID: 16902813 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials